FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996090129> ?p ?o ?g. }

• W2996090129 endingPage "1016" @default.
• W2996090129 startingPage "1009" @default.
• W2996090129 abstract "Abstract Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable platinum-resistant ovarian cancer. Patients and Methods: Patients received either G+C (guadecitabine 30 mg/m2 s.c. once-daily for 5 days and carboplatin) or treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) in 28-day cycles until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were RECIST v1.1 and CA-125 response rate, 6-month PFS, and overall survival (OS). Results: Of 100 patients treated, 51 received G+C and 49 received TC, of which 27 crossed over to G+C. The study did not meet its primary endpoint as the median PFS was not statistically different between arms (16.3 weeks vs. 9.1 weeks in the G+C and TC groups, respectively; P = 0.07). However, the 6-month PFS rate was significantly higher in the G+C group (37% vs. 11% in TC group; P = 0.003). The incidence of grade 3 or higher toxicity was similar in G+C and TC groups (51% and 49%, respectively), with neutropenia and leukopenia being more frequent in the G+C group. Conclusions: Although this trial did not show superiority for PFS of G+C versus TC, the 6-month PFS increased in G+C treated patients. Further refinement of this strategy should focus on identification of predictive markers for patient selection." @default.
• W2996090129 created "2019-12-26" @default.
• W2996090129 creator A5000521433 @default.
• W2996090129 creator A5001745177 @default.
• W2996090129 creator A5002181160 @default.
• W2996090129 creator A5003528816 @default.
• W2996090129 creator A5016686659 @default.
• W2996090129 creator A5017721654 @default.
• W2996090129 creator A5018001559 @default.
• W2996090129 creator A5018281504 @default.
• W2996090129 creator A5019816977 @default.
• W2996090129 creator A5024389718 @default.
• W2996090129 creator A5026047065 @default.
• W2996090129 creator A5033584583 @default.
• W2996090129 creator A5035033331 @default.
• W2996090129 creator A5036678244 @default.
• W2996090129 creator A5045094628 @default.
• W2996090129 creator A5046031005 @default.
• W2996090129 creator A5049011165 @default.
• W2996090129 creator A5055054082 @default.
• W2996090129 creator A5058249824 @default.
• W2996090129 creator A5061888144 @default.
• W2996090129 creator A5062151371 @default.
• W2996090129 creator A5065447416 @default.
• W2996090129 creator A5067743297 @default.
• W2996090129 creator A5068550336 @default.
• W2996090129 creator A5075566972 @default.
• W2996090129 creator A5081561534 @default.
• W2996090129 creator A5088144652 @default.
• W2996090129 creator A5090143508 @default.
• W2996090129 date "2020-03-01" @default.
• W2996090129 modified "2023-10-09" @default.
• W2996090129 title "A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer" @default.
• W2996090129 cites W1516613270 @default.
• W2996090129 cites W1635672209 @default.
• W2996090129 cites W1964644808 @default.
• W2996090129 cites W1991605202 @default.
• W2996090129 cites W1993463141 @default.
• W2996090129 cites W1997981312 @default.
• W2996090129 cites W2001643681 @default.
• W2996090129 cites W2019607817 @default.
• W2996090129 cites W2019865561 @default.
• W2996090129 cites W2034687480 @default.
• W2996090129 cites W2051658829 @default.
• W2996090129 cites W2061681410 @default.
• W2996090129 cites W2095916716 @default.
• W2996090129 cites W2097587005 @default.
• W2996090129 cites W2111836054 @default.
• W2996090129 cites W2113225141 @default.
• W2996090129 cites W2115528152 @default.
• W2996090129 cites W2124058261 @default.
• W2996090129 cites W2131099997 @default.
• W2996090129 cites W2132119564 @default.
• W2996090129 cites W2136753100 @default.
• W2996090129 cites W2150136461 @default.
• W2996090129 cites W2151783390 @default.
• W2996090129 cites W2163710445 @default.
• W2996090129 cites W2170928115 @default.
• W2996090129 cites W22029415 @default.
• W2996090129 cites W2560067501 @default.
• W2996090129 cites W2773709091 @default.
• W2996090129 cites W2793022348 @default.
• W2996090129 cites W2886023125 @default.
• W2996090129 cites W2902849689 @default.
• W2996090129 cites W4234338065 @default.
• W2996090129 cites W4376561984 @default.
• W2996090129 doi "https://doi.org/10.1158/1078-0432.ccr-19-1638" @default.
• W2996090129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7056559" @default.
• W2996090129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31831561" @default.
• W2996090129 hasPublicationYear "2020" @default.
• W2996090129 type Work @default.
• W2996090129 sameAs 2996090129 @default.
• W2996090129 citedByCount "51" @default.
• W2996090129 countsByYear W29960901292020 @default.
• W2996090129 countsByYear W29960901292021 @default.
• W2996090129 countsByYear W29960901292022 @default.
• W2996090129 countsByYear W29960901292023 @default.
• W2996090129 crossrefType "journal-article" @default.
• W2996090129 hasAuthorship W2996090129A5000521433 @default.
• W2996090129 hasAuthorship W2996090129A5001745177 @default.
• W2996090129 hasAuthorship W2996090129A5002181160 @default.
• W2996090129 hasAuthorship W2996090129A5003528816 @default.
• W2996090129 hasAuthorship W2996090129A5016686659 @default.
• W2996090129 hasAuthorship W2996090129A5017721654 @default.
• W2996090129 hasAuthorship W2996090129A5018001559 @default.
• W2996090129 hasAuthorship W2996090129A5018281504 @default.
• W2996090129 hasAuthorship W2996090129A5019816977 @default.
• W2996090129 hasAuthorship W2996090129A5024389718 @default.
• W2996090129 hasAuthorship W2996090129A5026047065 @default.
• W2996090129 hasAuthorship W2996090129A5033584583 @default.
• W2996090129 hasAuthorship W2996090129A5035033331 @default.
• W2996090129 hasAuthorship W2996090129A5036678244 @default.
• W2996090129 hasAuthorship W2996090129A5045094628 @default.
• W2996090129 hasAuthorship W2996090129A5046031005 @default.
• W2996090129 hasAuthorship W2996090129A5049011165 @default.
• W2996090129 hasAuthorship W2996090129A5055054082 @default.
• W2996090129 hasAuthorship W2996090129A5058249824 @default.
• W2996090129 hasAuthorship W2996090129A5061888144 @default.

• next